

# Epithelial Ovarian Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/EF341D973CCAEN.html>

Date: May 2024

Pages: 134

Price: US\$ 6,499.00 (Single User License)

ID: EF341D973CCAEN

## Abstracts

The 7 major epithelial ovarian cancer markets reached a value of US\$ 2.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 14.3 Billion by 2034, exhibiting a growth rate (CAGR) of 18.2% during 2024-2034.

The epithelial ovarian cancer market has been comprehensively analyzed in IMARC's new report titled "Epithelial Ovarian Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Epithelial ovarian cancer, also referred to as ovarian carcinoma, is a type of cancer that originates from the epithelial cells that line the outer surface of the ovaries. It often presents with nonspecific symptoms, which can make early disease detection a bit challenging. Some of the common indications associated with the ailment include abdominal bloating or discomfort, pelvic pain or pressure, changes in bowel or bladder habits, feeling full quickly while eating, unexplained weight loss, fatigue, changes in menstrual cycles, etc. Diagnosing epithelial ovarian cancer typically involves a combination of medical history assessment, physical examination, imaging tests, and tissue sampling. The process begins with a thorough evaluation of the patient's symptoms, medical history, and risk factors. A pelvic examination may be performed to check the condition of the ovaries. Numerous imaging procedures, such as transvaginal ultrasound, CT scan, MRI, etc., are used to visualize the ovaries and assess the extent of the disease. A biopsy is usually conducted to confirm the diagnosis, which helps to determine the type of ovarian cancer, its grade, and its stage. Additionally, genetic testing may be recommended to identify inherited gene mutations that could influence treatment decisions and guide genetic counseling.

The increasing cases of inherited gene mutations, particularly in the BRCA1 and

BRCA2 genes, that disrupt the DNA repair process and lead to an accumulation of genetic errors, are primarily driving the epithelial ovarian cancer market. Besides this, the rising prevalence of several associated risk factors, such as long-term use of estrogen-only hormone replacement therapy, endometriosis, family history, obesity, etc., is creating a positive outlook for the market. Furthermore, the escalating usage of hormone therapy, which involves the use of medications that either block the production of hormones or interfere with their action, thereby slowing down the development of tumor, is also bolstering the market growth. Apart from this, the emerging popularity of intraperitoneal chemotherapy, since it delivers the chemotherapy drugs directly into the abdominal cavity and allows for higher drug concentrations in the area where ovarian cancer is most likely to spread, is acting as another significant growth-inducing factor. Moreover, the ongoing advancements in surgical techniques, including the introduction of precision-guided surgery and sentinel lymph node mapping, which aim to improve the extent of tumor removal while preserving healthy tissue and achieving optimal debulking, are expected to drive the epithelial ovarian cancer market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the epithelial ovarian cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for epithelial ovarian cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the epithelial ovarian cancer market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States  
Germany  
France  
United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the epithelial ovarian cancer market  
Historical, current, and future performance of various therapeutic categories in the market  
Sales of various drugs across the epithelial ovarian cancer market  
Reimbursement scenario in the market  
In-market and pipeline drugs  
Competitive Landscape:  
This report also provides a detailed analysis of the current epithelial ovarian cancer marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

## Key Questions Answered in this Report:

### Market Insights

How has the epithelial ovarian cancer market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the epithelial ovarian cancer market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the epithelial ovarian cancer market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of epithelial ovarian cancer across the seven major markets?

What is the number of prevalent cases (2018-2034) of epithelial ovarian cancer by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of epithelial ovarian cancer by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with epithelial ovarian cancer across the seven major markets?

What is the size of the epithelial ovarian cancer patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of epithelial ovarian cancer?

What will be the growth rate of patients across the seven major markets?

### Epithelial Ovarian Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for epithelial ovarian cancer drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the epithelial ovarian cancer market?

What are the key regulatory events related to the epithelial ovarian cancer market?

What is the structure of clinical trial landscape by status related to the epithelial ovarian cancer market?

What is the structure of clinical trial landscape by phase related to the epithelial ovarian cancer market?

What is the structure of clinical trial landscape by route of administration related to the epithelial ovarian cancer market?

## Contents

### 1 PREFACE

### 2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### 3 EXECUTIVE SUMMARY

### 4 EPITHELIAL OVARIAN CANCER - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### 5 EPITHELIAL OVARIAN CANCER - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### 6 PATIENT JOURNEY

### 7 EPITHELIAL OVARIAN CANCER - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 EPITHELIAL OVARIAN CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 EPITHELIAL OVARIAN CANCER - UNMET NEEDS**

## **10 EPITHELIAL OVARIAN CANCER - KEY ENDPOINTS OF TREATMENT**

## **11 EPITHELIAL OVARIAN CANCER - MARKETED PRODUCTS**

- 11.1 List of Epithelial Ovarian Cancer Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Lynparza (Olaparib) - AstraZeneca
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets
  - 11.1.2 Rubraca (Rucaparib) - Clovis Oncology
    - 11.1.2.1 Drug Overview



- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Zejula (Niraparib) - Janssen/Merck/GlaxoSmithKline
  - 11.1.3.1 Drug Overview
  - 11.1.3.2 Mechanism of Action
  - 11.1.3.3 Regulatory Status
  - 11.1.3.4 Clinical Trial Results
  - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Avastin (Bevacizumab) - Genentech/Roche
  - 11.1.4.1 Drug Overview
  - 11.1.4.2 Mechanism of Action
  - 11.1.4.3 Regulatory Status
  - 11.1.4.4 Clinical Trial Results
  - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Elahere (Mirvetuximab soravtansine) - ImmunoGen
  - 11.1.5.1 Drug Overview
  - 11.1.5.2 Mechanism of Action
  - 11.1.5.3 Regulatory Status
  - 11.1.5.4 Clinical Trial Results
  - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## **12 EPITHELIAL OVARIAN CANCER - PIPELINE DRUGS**

- 12.1 List of Epithelial Ovarian Cancer Pipeline Drugs Across the Top 7 Markets
  - 12.1.1 MK-1775 - AstraZeneca
    - 12.1.1.1 Drug Overview
    - 12.1.1.2 Mechanism of Action
    - 12.1.1.3 Clinical Trial Results
    - 12.1.1.4 Safety and Efficacy
    - 12.1.1.5 Regulatory Status
  - 12.1.2 IMNN 001 - Imunon
    - 12.1.2.1 Drug Overview
    - 12.1.2.2 Mechanism of Action
    - 12.1.2.3 Clinical Trial Results
    - 12.1.2.4 Safety and Efficacy

- 12.1.2.5 Regulatory Status
- 12.1.3 ITIL306 - Instil Bio
  - 12.1.3.1 Drug Overview
  - 12.1.3.2 Mechanism of Action
  - 12.1.3.3 Clinical Trial Results
  - 12.1.3.4 Safety and Efficacy
  - 12.1.3.5 Regulatory Status
- 12.1.4 DPX Survivac - ImmunoVaccine Technologies
  - 12.1.4.1 Drug Overview
  - 12.1.4.2 Mechanism of Action
  - 12.1.4.3 Clinical Trial Results
  - 12.1.4.4 Safety and Efficacy
  - 12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. EPITHELIAL OVARIAN CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. EPITHELIAL OVARIAN CANCER – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

## **15 EPITHELIAL OVARIAN CANCER - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Epithelial Ovarian Cancer - Market Size
    - 15.2.1.1 Market Size (2018-2023)
    - 15.2.1.2 Market Forecast (2024-2034)
  - 15.2.2 Epithelial Ovarian Cancer - Market Size by Therapies
    - 15.2.2.1 Market Size by Therapies (2018-2023)
    - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Epithelial Ovarian Cancer - Market Size
    - 15.3.1.1 Market Size (2018-2023)

- 15.3.1.2 Market Forecast (2024-2034)
- 15.3.2 Epithelial Ovarian Cancer - Market Size by Therapies
  - 15.3.2.1 Market Size by Therapies (2018-2023)
  - 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Epithelial Ovarian Cancer - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Epithelial Ovarian Cancer - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Epithelial Ovarian Cancer - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Epithelial Ovarian Cancer - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Epithelial Ovarian Cancer - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Epithelial Ovarian Cancer - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Epithelial Ovarian Cancer - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Epithelial Ovarian Cancer - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Epithelial Ovarian Cancer - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Epithelial Ovarian Cancer - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Epithelial Ovarian Cancer - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Epithelial Ovarian Cancer - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Epithelial Ovarian Cancer - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Epithelial Ovarian Cancer - Market Size

- 15.8.1.1 Market Size (2018-2023)
- 15.8.1.2 Market Forecast (2024-2034)
- 15.8.2 Epithelial Ovarian Cancer - Market Size by Therapies
  - 15.8.2.1 Market Size by Therapies (2018-2023)
  - 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Epithelial Ovarian Cancer - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Epithelial Ovarian Cancer - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Epithelial Ovarian Cancer - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Epithelial Ovarian Cancer - Access and Reimbursement Overview

## **16 EPITHELIAL OVARIAN CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 EPITHELIAL OVARIAN CANCER MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 EPITHELIAL OVARIAN CANCER MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Epithelial Ovarian Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/EF341D973CCAEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EF341D973CCAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

